Cellares Fires Back After Bristol Myers Exits Cell Therapy Deal

Cell therapy manufacturing startup Cellares publicly rebuked Bristol Myers Squibb (NYSE: BMY) after the drugmaker terminated their manufacturing contract, claiming Cellares' commercial manufacturing technology fell short of requirements; BMY shares last closed at $67.57, down 0.52% on Aug. 26, 2026.

A rare public fight has broken out between a large pharmaceutical company and one of its manufacturing suppliers. Bristol Myers Squibb (NYSE: BMY) has ended its contract with Cellares, a privately held cell therapy manufacturing startup, telling the market that Cellares' commercial manufacturing technology did not meet the standard the drugmaker required. Cellares has refused to let the characterisation stand, and is publicly rebuking it.

Disputes like this are usually settled quietly. Contract manufacturing relationships in biologics and cell therapy are governed by quality agreements, batch records and audit findings — documents that almost never see daylight. That both sides are now arguing in the open, as reported by Endpoints News, tells you how much is riding on the reputational question underneath: whether automated, closed-system cell therapy manufacturing is actually ready for commercial-scale production.

Why a manufacturing contract became a public argument

For a startup whose entire commercial proposition rests on the credibility of its production platform, a named criticism from a company of Bristol Myers Squibb's size is not a routine commercial setback. It is an argument about whether the technology works. Cellares cannot afford to leave that unanswered, because every prospective partner evaluating its capacity will now ask about it in diligence.

For Bristol Myers Squibb, the calculus is different. The company is one of the more established players in approved cell therapies, and its manufacturing decisions carry weight precisely because it has run the process at commercial scale itself. When a firm with that history says an outsourced platform is not up to scratch, other potential customers listen — which is exactly why Cellares is contesting the framing rather than absorbing it.

What the lost contract does to a capacity buildout

Cell therapy manufacturing capacity is capital-intensive and built ahead of demand. Facilities, clean-room suites and automated production systems are commissioned years before the batches that fill them are ordered. That business model depends on anchor customers: large pharmaceutical partners whose committed volume underwrites the fixed cost of the buildout and gives lenders and equity investors something to price.

Losing an anchor of that size does two things at once. It removes contracted volume from the forward book, and it raises the cost of replacing that volume, because the next customer will negotiate with the termination in view. The lead does not disclose the contract's financial terms, the volumes involved, or what portion of Cellares' committed capacity Bristol Myers Squibb represented — so the size of the hole is not public. What is public is that the partnership has ended.

The practical questions for Cellares' remaining partners are narrower than the headline fight suggests:

• Whether the shortcoming Bristol Myers Squibb alleges is specific to one product and process, or generic to the platform.
• Whether any regulatory filing or inspection finding sits behind the decision, or whether it was a commercial judgement.
• Whether freed-up capacity gets reallocated to existing customers or sits idle.
• Whether Cellares' funding runway assumed this revenue.

Where Bristol Myers Squibb shares stand

The dispute has not registered as a market event for the buyer. Bristol Myers Squibb last closed at $67.57, down 0.52% from the prior close of $67.92, with a session range of $67.32 to $68.00, as of 20:00 GMT on Aug. 26, 2026. That is a quiet day by any measure, and softer than the broad market: the S&P 500 tracker (SPY) finished at $766.08, up 0.02%, and the Nasdaq 100 tracker (QQQ) closed at $711.37, up 0.09%. The Dow tracker (DIA) closed at $534.23, down 0.19%.

The asymmetry is the point. For a company of Bristol Myers Squibb's scale, switching a manufacturing supplier is an operational decision that does not move the share price. For Cellares — private, pre-scale and selling a technology thesis — the same decision is existential in a way no ticker will show you.

The wider question about automated cell therapy production

Autologous cell therapies, made from a single patient's own cells, are the hardest thing in modern biomanufacturing to industrialise. Each batch is a lot of one. Costs are high, turnaround times are long, and manual, technician-heavy processes are the bottleneck that has kept approved therapies expensive and slow to deliver. The entire investment case for automated, closed-loop manufacturing platforms is that they break that bottleneck.

That case has attracted substantial private capital across the sector on the promise of throughput and consistency that manual suites cannot match. What has been thinner on the ground is demonstrated commercial-scale performance under a large pharma's quality regime — the difference between running a process well in a demonstration facility and running it repeatedly, in compliance, for a marketed product with patients waiting.

This dispute lands directly on that gap. If Cellares' rebuttal is persuasive and detailed, it reframes the episode as a commercial disagreement between two companies. If it is not, the read-through extends past Cellares to every venture-funded platform selling the same promise, and to the pharmaceutical companies deciding whether to outsource or keep manufacturing in-house.

What to watch from here

Three things will settle how this is remembered. First, the substance of Cellares' technical response: whether it addresses the specific criticism or answers a general one. Second, whether Bristol Myers Squibb says anything further, or lets the termination speak and moves on — large pharma typically prefers the latter. Third, and most telling, whether Cellares announces a replacement partner. A new commercial contract does more to rebut the criticism than any statement.

Also worth tracking is whether the dispute becomes a legal one. Termination clauses in manufacturing agreements typically turn on defined performance and quality standards, and a disagreement over whether those standards were met is the sort of thing that ends up in arbitration. Neither side has indicated that path in what is public so far.

For investors in the listed name, this is a footnote. For the private cell therapy manufacturing sector, it is the first time the readiness question has been asked out loud by a customer with the standing to make it stick — and the answer will shape fundraising conversations well beyond the two companies involved.

Key facts

• BMY last close: $67.57, -0.52% as of 20:00 GMT, Aug. 26, 2026
• BMY day range: $67.32 – $68.00 (prev close $67.92)
• Contract status: Bristol Myers Squibb terminated its agreement with Cellares; partnership ended
• Cellares' position: Publicly rebuking the claim that its commercial manufacturing technology fell short

Frequently asked questions

What is the dispute between Cellares and Bristol Myers Squibb about?

Bristol Myers Squibb pulled out of its manufacturing contract with Cellares, saying the startup's commercial cell therapy manufacturing technology was not up to scratch. Cellares has publicly rejected that characterisation and is defending its platform. The partnership has ended. Financial terms of the contract and the volumes involved have not been made public.

Is Cellares a publicly traded company?

No. Cellares is a privately held cell therapy manufacturing startup, so there is no listed share price to reflect the impact of losing the Bristol Myers Squibb contract. Bristol Myers Squibb is the listed party in the dispute, trading on the NYSE under the ticker BMY.

How did Bristol Myers Squibb stock react?

There was no meaningful market reaction. BMY last closed at $67.57 on Aug. 26, 2026, down 0.52% from the prior close of $67.92, within a session range of $67.32 to $68.00. That was slightly softer than the broad market, with the S&P 500 tracker up 0.02% and the Nasdaq 100 tracker up 0.09% on the day.

Why is cell therapy manufacturing so difficult to automate?

Autologous cell therapies are made from an individual patient's own cells, so every batch is effectively a lot of one. That makes conventional scale-up impossible and leaves production labour-intensive, slow and expensive. Automated closed-system platforms aim to solve this, but proving consistent performance at commercial scale under a large pharmaceutical company's quality regime remains the hurdle.

What happens to Cellares' manufacturing capacity now?

Capacity underwritten by the Bristol Myers Squibb contract is no longer committed. Cell therapy facilities are built ahead of demand, so anchor customers are what justify the fixed cost. Cellares will need either to reallocate that capacity to existing partners or win replacement volume, and it will negotiate with the termination publicly known.

What should observers watch next in this dispute?

Three signals matter: how technically specific Cellares' rebuttal is, whether Bristol Myers Squibb responds further or lets the termination stand, and whether Cellares announces a replacement commercial partner. A new contract would rebut the criticism more effectively than any statement. Whether the disagreement moves to arbitration is also worth tracking.

Sources

• Cellares rebukes Bristol Myers' criticism of its cell therapy technology — Endpoints News

Photo: ThisIsEngineering · Pexels Licence — source